Loading
Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies.
Andrea Necchi led PURE-01, which showed neoadjuvant pembrolizumab alone produces pathological complete responses in more than a third of muscle-invasive bladder cancers and defined biomarkers of response, and is a lead investigator of the KEYNOTE-057 and SunRISe programmes in non-muscle-invasive disease. He heads GU oncology at San Raffaele and studies bladder-sparing strategies.
Shares PD-1, Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag urothelial.
Shares PD-1, Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag urothelial.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag neoadjuvant.
Shares PD-1, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag urothelial.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag neoadjuvant.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag neoadjuvant.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag italy.
Shares PD-1, Immune checkpoint inhibitors and the tag neoadjuvant.